CD8A and neoplasm: CY1-4 is a small molecule IDO/TDO inhibitor [40], which can effectively inhibit IDO/TDO-mediated immune resistance, relieve immunosuppressive TME and TDLN, significantly reduce Tregs, increase CD4+ T cells and CD8+ T cells, and improve the anti-tumor effect.